Browse studies

Find your next paid study

335 recruiting studies matching your filters

An Adaptive Design for Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized Trial

The purpose of this study is to assess the best time to deliver a message to increase physical activity and how often participants will experience a pain episo…

Breast CancerCervical CancerBladder Cancer+4 more

Estimated

~$10 – $6,250

Medical College of WisconsinNCT07227077

Phase 2

A Randomized, Open-Label, Phase 2/3 Study of Datopotamab Deruxtecan (Dato-DXd) Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) Who Progressed During or After Enfortumab Vedotin (EV) Plus Pembrolizumab Combination Treatment TROPION-Urothelial03 (TU03)

This is a global, multicenter, randomized, open-label, Phase 2/3 study of Dato-DXd plus carboplatin or cisplatin versus gemcitabine plus carboplatin or cisplat…

Urothelial CancerBladder Cancer

Estimated

~$10 – $7,500

Daiichi SankyoNCT07129993

University of California Minority Patient-Derived Xenograft (PDX) Development and Trial Center (UCaMP) to Reduce Cancer Health Disparities

This trial establishes patient-derived cancer xenografts in addressing cancer health and treatment disparities that disproportionately affect racial/ethnic min…

Bladder CarcinomaGastric CarcinomaLiver and Intrahepatic Bile Duct Carcinoma+2 more

Estimated

~$10 – $750

University of California, DavisNCT04410302

Phase 1

FORAGER-1: A Phase 1, Open-Label, Multicenter Study of Vepugratinib (LY3866288; LOXO-435) in Locally Advanced or Metastatic Solid Tumors Including Urothelial Cancer and Muscle Invasive Bladder Cancer With FGFR3 Alterations

The main purpose of this study is to learn more about the safety, side effects, and effectiveness of Vepugratinib by itself or when it is combined with other m…

Urinary Bladder NeoplasmsNeoplasm MetastasisUreteral Neoplasms

Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT05614739

Phase 3

COMparative Prospective Assessment Through Clinically Integrated Randomized Trials Evaluating Intravesical Treatments: The COMPARE IT Trial

The purpose of this study is to compare the effectiveness of different FDA-approved/NCCN-recommended drug treatments for NMIBC. In particular, the FDA-approved…

Non-Muscle Invasive Bladder Cancer

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT06929286

Phase 4

Methenamine Hippurate Compared to Typical Antibiotic Prophylaxis in the Prevention of Urinary Tract Infection Following Intradetrusor OnabotulinumtoxinA Injection for Treatment of Overactive Bladder: a Randomized Controlled Non-Inferiority Trial

The goal of this clinical trial is to compare methenamine hippurate prophylaxis to routine antibiotic prophylaxis following onabotulinumtoxinA (BOTOX-A) inject…

Overactive Bladder (OAB)Urinary Tract Infection (Diagnosis)

Estimated

~$10 – $6,250

Women and Infants Hospital of Rhode IslandNCT06953271

Measuring Surgical Recovery After Radical Cystectomy

The intent of this study is to establish a registry of post-surgical outcomes in patients undergoing radical cystectomy at MD Anderson Cancer Center and the co…

Bladder Cancer

Estimated

~$10 – $750

M.D. Anderson Cancer CenterNCT03193970

Phase 2

An Open-Label, International, Multicenter Phase II Study to Evaluate the Efficacy and Safety of Intravesical T3011 Injection in Participants With BCG-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) or BCG-Exposed, Chemotherapy-Unresponsive Intermediate /High-Risk NMIBC

This is a Phase II clinical study to evaluate the efficacy and safety of intravesical T3011 injection in participants with BCG-unresponsive high-risk NMIBC or …

Nonmuscle-invasive Bladder Cancer

Estimated

~$10 – $8,750

ImmVira Pharma Co. LtdNCT06971614

Phase 2

Neoadjuvant STereotActic Body Radiotherapy and Cemiplimab With or Without Fianlimab for Cisplatin-Ineligible or Cisplatin-Declining Patients With Muscle-Invasive Bladder Cancer (NeoSTAR Bladder)

The researchers are doing this study to find out whether stereotactic body radiation therapy (SBRT) in combination with immunotherapy (cemiplimab with or witho…

Bladder Urothelial Carcinoma

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT07414992

Phase 3

The Phase III Adaptive Radiation and Chemotherapy for Muscle Invasive Bladder Cancer Trial (ARCHER)

This phase III trial compares the effect of decreased number of radiation (ultra-hypofractionated) treatments to the usual radiation number of treatments (hypo…

Muscle Invasive Bladder Urothelial CarcinomaStage II Bladder Cancer AJCC v8Stage IIIA Bladder Cancer AJCC v8

Estimated

~$10 – $7,500

NRG OncologyNCT07097142

InAdvance: Surveillance, Prevention, and Interception in a Population at Risk For Cancer

This research study is creating a way to collect and store specimens and information from participants who may be at an increased risk of developing cancer, or…

Cancer RiskCancer Predisposition SyndromeHereditary Cancer Prediction+28 more

Estimated

~$10 – $1,125

Phase 1

A Phase I Trial of Cancer-targeting Micelles for Non-myoinvasive Bladder Cancer

This clinical trial is to determine the safety and effectiveness of an investigational bladder cancer drug named "PLZ4-coated paclitaxel-loaded nanoscale micel…

Non-muscle-invasive Bladder Cancer

Estimated

~$10 – $5,625

VA Office of Research and DevelopmentNCT05519241